German Guidelines on Screening, Diagnosis, and Treatment of Alcohol Use Disorders: Update 2021.


Journal

European addiction research
ISSN: 1421-9891
Titre abrégé: Eur Addict Res
Pays: Switzerland
ID NLM: 9502920

Informations de publication

Date de publication:
2022
Historique:
received: 29 07 2021
accepted: 28 01 2022
pubmed: 20 4 2022
medline: 24 6 2022
entrez: 19 4 2022
Statut: ppublish

Résumé

Alcohol consumption in Germany is associated with considerable health and economic consequences. In addition to prevention, the early detection and differential treatment of those affected play an important role. The guideline "Screening, Diagnosis, and Treatment of Alcohol Use Disorders" forms the basis of this care for people suffering from alcohol use disorders. Regular updates integrate the current state of research evidence and clinical expertise. Under the auspices of the German Society for Psychiatry, Psychotherapy, Psychosomatics, and Neurology and the German Society for Addiction Research and Addiction Therapy e.V. (DG-Sucht), the 2019-2020 S3 guideline on alcohol was revised by eight working groups. Thirty-five professional societies participated in a structured consensus process to deliberate the recommendations. Potential conflicts of interest were examined in advance, documented, and taken into account during the voting on the recommendations. The guideline provides recommendations on screening and brief interventions for different groups of people, as well as on treatment of individuals in the acute and post-acute phases of withdrawal. Special emphasis was placed on the treatment of comorbid somatic and psychological disorders. In addition, recommendations for specific groups of people (e.g., children and adolescents, pregnant women) have been made and adapted to the German care landscape.

Identifiants

pubmed: 35439764
pii: 000522335
doi: 10.1159/000522335
doi:

Types de publication

Practice Guideline Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

309-322

Informations de copyright

© 2022 S. Karger AG, Basel.

Auteurs

Falk Kiefer (F)

Central Institute of Mental Health, Department of Addictive Behaviour and Addiction Medicine, Mannheim, Germany.
Chair in Addiction Research, Medical Faculty Mannheim/Heidelberg University, University of Heidelberg, Heidelberg, Germany.

Anil Batra (A)

Department of Psychiatry and Psychotherapy, University Hospital Tuebingen, Tuebingen, Germany.

Kay Uwe Petersen (KU)

Department of Psychiatry and Psychotherapy, University Hospital Tuebingen, Tuebingen, Germany.

Isabel Sophie Ardern (IS)

Central Institute of Mental Health, Department of Addictive Behaviour and Addiction Medicine, Mannheim, Germany.

Daniela Tananska (D)

Central Institute of Mental Health, Department of Addictive Behaviour and Addiction Medicine, Mannheim, Germany.

Gallus Bischof (G)

Department of Psychiatry and Psychotherapy, University of Lübeck, Lübeck, Germany.

Wilma Funke (W)

MEDIAN clinic Wied, Rhineland-Palatinate, Germany.

Johannes Lindenmeyer (J)

Salus Clinc Lindow, Lindow, Germany.

Sebastian Mueller (S)

Center of Alcohol Research, Heidelberg University Hospital, Heidelberg, Germany.

Ulrich W Preuss (UW)

Vitos clinic for psychiatry an psychotherapy Herborn, Herborn, Germany.

Martin Schäfer (M)

Department of Psychiatry and Psychotherapy, Psychosomatic and Addiction Medicine, Kliniken Essen-Mitte, Essen, Germany.

Rainer Thomasius (R)

German Center for Addiction Research in Childhood and Adolescence (DZSKJ), University Medical Center Hamburg-Eppendorf (UKE), Hamburg, Germany.

Clemens Veltrup (C)

Fachklinik Freudenholm-Ruhleben, Schellhorn, Germany.

Volker Weissinger (V)

Fachverband Sucht e.V., Bonn, Germany.

Norbert Wodarz (N)

Clinical Addiction Medicine Department of Psychiatry and Psychotherapy, University of Regensburg, Regensburg, Germany.

Friedrich M Wurst (FM)

Medical Faculty, Psychiatry and Psychotherapy, University of Basel, Basel, Switzerland.

Sabine Hoffmann (S)

Central Institute of Mental Health, Department of Addictive Behaviour and Addiction Medicine, Mannheim, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH